Previous 10 | Next 10 |
Agreement pairs Norgine’s commercial expertise and leading European footprint with PEDMARQSI ® , the first and only approved therapy in the European Union and U.K. for reducing the risk of cisplatin-induced hearing loss in pediatric patients with localized, non-metastatic soli...
2024-03-12 10:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-06 20:39:28 ET Summary Fennec released sales guidance for Q4 2023, exceeded analyst expectations. A pending EU launch of PEDMARK® provides a near term opportunity for the Company to finalize an EU partnership. Revenue growth in the US, and completion of a Japanese...
~ Fourth Quarter 2023 Net Revenues of Approximately $9.2 to $9.7 Million ~ ~ Company Expects to Report 2023 Fourth Quarter and Audited Full-Year Results on or about March 26, 2024 ~ RESEARCH TRIANGLE PARK, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NA...
RESEARCH TRIANGLE PARK, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has issued a public reminder to healthcare providers that PED...
2024-01-29 16:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-12-07 15:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
~ Supports Strategic Discussions and Global Launch Activities ~ ~ Extends Access to Additional Undrawn Capital As Needed During Global PEDMARK ® Rollout ~ ~ Facilitates Market Expansion into the Adolescent and Young Adult (AYA) Patient Population ~ RESEARCH TRIANG...
2023-11-10 08:59:44 ET More on Fennec Pharmaceuticals Fennec Pharmaceuticals Expands Possible TAM Significantly Historical earnings data for Fennec Pharmaceuticals For further details see: Fennec files $90M common shares offering
2023-11-09 18:24:46 ET Summary Fennec Pharmaceuticals is a commercial-stage biotech company with a single drug, PEDMARK®, which is FDA-approved to reduce the risk of hearing loss in pediatric cancer patients. The company faced challenges and delays in obtaining FDA approval b...
News, Short Squeeze, Breakout and More Instantly...
Fennec Pharmaceuticals Inc. Company Name:
FENC Stock Symbol:
NASDAQ Market:
Fennec Pharmaceuticals Inc. Website:
RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty ...
RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2024 financial results before the opening of the U.S. financial...
2024-04-21 10:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...